Home > > > Intravenous Immunoglobulin Market Projected for Strong Growth Through 2034

Intravenous Immunoglobulin Market Projected for Strong Growth Through 2034

Author : John snow | Published On : 30 Jul 2026

Intravenous Immunoglobulin Market Insights, Epidemiology, and Market Forecast–2034

The intravenous immunoglobulin (IVIG) market is witnessing steady and significant growth, supported by heightened awareness of immune-related disorders, a rising incidence of immunodeficiency conditions, and continued therapeutic innovation from leading pharmaceutical companies such as CSL Behring, Grifols, Octapharma, Kedrion, Takeda Pharmaceutical, Baxter International, ADMA Biologics, LFB Biotechnologies, Biotest AG, Shanghai RAAS Blood Products, China Biologics Products, BDI Pharma, and Intas Pharmaceuticals, among others.

DelveInsight’s “Intravenous Immunoglobulin Market Insights, Epidemiology, and Market Forecast–2034” report provides a comprehensive evaluation of the IVIG treatment landscape, including historical and projected epidemiological data and detailed market trends across the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. The study thoroughly assesses existing treatment standards, pipeline candidates, individual therapy market shares, and IVIG market projections through 2034, offering valuable intelligence for stakeholders operating in this vital therapeutic segment.

According to DelveInsight’s findings, the IVIG market is positioned for long-term expansion due to a combination of factors, including deeper insights into disease pathophysiology, technological advancements in plasma sourcing and manufacturing processes, and a growing population of patients requiring immunoglobulin replacement therapy. The increasing prevalence of conditions such as primary immunodeficiency diseases, along with improvements in diagnostic infrastructure, continues to accelerate market growth.

Download the Intravenous Immunoglobulin Market report to explore the key factors driving the IVIG therapeutic landscape @ Intravenous Immunoglobulin Market Trends - https://www.delveinsight.com/sample-request/intravenous-immunoglobulin-market?utm_source=apac&utm_medium=pressrelease&utm_campaign=akpr 

Intravenous Immunoglobulin Epidemiology

The DelveInsight report delivers detailed epidemiological assessments covering both historical and current IVIG patient populations, along with forecasted trends across the seven major markets (7MM). The analysis highlights notable regional differences in patient distribution, with North America maintaining a dominant share of the overall market.

The epidemiology section examines the drivers behind current and projected trends through a combination of published studies and key opinion leader insights. It includes diagnosed patient pool estimates and clearly outlines the assumptions supporting these projections.

Patients eligible for IVIG therapy are categorized across multiple indications, including primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy (CIDP), hypogammaglobulinemia, Kawasaki disease, myasthenia gravis, and several autoimmune disorders. Among these, primary immunodeficiency diseases represent the largest revenue-generating segment, while Kawasaki disease is anticipated to demonstrate the most rapid growth over the forecast timeline.

Explore shifting patterns in IVIG patient pool projections @ Intravenous Immunoglobulin Epidemiology Analysis - https://www.delveinsight.com/sample-request/intravenous-immunoglobulin-market?utm_source=apac&utm_medium=pressrelease&utm_campaign=akpr 

Treatment Landscape and Pipeline Developments

The IVIG treatment ecosystem includes both established marketed therapies and promising late-stage pipeline candidates. The drug-focused segment of the report offers in-depth insights into approved IVIG products as well as Phase II and Phase III candidates, detailing clinical trial progress, mechanisms of action, regulatory milestones, and competitive positioning.

Recent advancements underscore the evolving nature of the IVIG space. For example, Evolve Biologics has completed a Phase III clinical study for its IVIG product, with regulatory filing anticipated in 2027. This marks a notable development in plasma-derived therapy, leveraging the company’s proprietary PlasmaCap EBA purification platform.

Broader pipeline analysis indicates continued exploration of innovative therapeutic strategies aimed at improving disease outcomes. Industry leaders—including CSL Behring, Grifols, Octapharma, Kedrion, Takeda Pharmaceutical, Baxter International, ADMA Biologics, LFB Biotechnologies, Biotest AG, Shanghai RAAS Blood Products, China Biologics Products, BDI Pharma, and Intas Pharmaceuticals—are actively investing in next-generation IVIG formulations designed to enhance efficacy, safety, and patient convenience.

1. Takeda Pharmaceutical Company Limited

Company & Country:
Takeda Pharmaceutical Company Limited — Japan (Headquarters in Tokyo/Osaka)

Product / Drug Candidate:

  • Immune Globulin (liquid IVIG), including Kenketsu GLOVENIN-I 10% (IVIG)

  • HYQVIA® (facilitated subcutaneous immunoglobulin / fSCIG) (IVIG + recombinant hyaluronidase)

Clinical Trial Phases & Registry IDs:

  • Phase 3:

    • Liquid IVIG (improved Kenketsu GLOVENIN-I 10% IV formulation) — regulatory approval achieved in Japan (new formulation) with supportive Phase 3 data (JMA reviews).

  • Phase 3 (SCIG / fSCIG):

    • HYQVIA® pivotal Phase 3 trials included NCT05150340 and NCT05513586 for agammaglobulinemia/hypogammaglobulinemia in Japan (registrations listed in press releases).

  • Long-term Extension / Maintenance (Phase 3 / ongoing):

    • ADVANCE-CIDP 3 (Phase 3 extension in chronic inflammatory demyelinating polyneuropathy) leveraging HYQVIA (NCT02955355).

Mechanism of Action (MOA):

  • IVIG / Immune Globulin: Polyclonal human IgG pooled from plasma donors that provides immune replacement (in immunodeficiency) and immunomodulatory effects via Fc receptor blockade, anti-idiotype interactions, and cytokine modulation.

  • HYQVIA: Combines IVIG with recombinant human hyaluronidase (rHuPH20) to enhance dispersion and absorption subcutaneously — functionally similar immunoglobulin replacement with improved delivery characteristics.

Latest News / Updates:

  • Approval of Kenketsu GLOVENIN-I 10% IVIG in Japan (Feb 2026), reflecting regulatory advancement of improved IVIG formulation.

  • Multiple Phase 3 outcomes supporting safety and expanded clinical utility of HYQVIA in immunodeficiency and neuroinflammatory disorders.

Regulatory:

  • Japanese Ministry of Health, Labour and Welfare approvals for Kenketsu GLOVENIN-I liquid IVIG and HYQVIA fSCIG.

2. GC Biopharma (Green Cross Corporation)

Product / Drug Candidate:

  • Plasma-derived IVIG • Plasma Proteins developed as biologic therapies (e.g., IVIG products) — specific clinical registry entries historically include Green Cross IVIG formulations.

Clinical Trial Phases & Registry IDs:

  • Phase 3:

    • An Open Phase 3 Study of IV-Globulin SN Inj.10% to treat immune thrombocytopenia (Clinical registry entry).

Mechanism of Action (MOA):

  • Human plasma-derived immunoglobulin G (IgG) acts as replacement therapy and immunomodulator in autoimmune and immunodeficiency conditions, facilitating neutralization of auto-antibodies and modulation of immune effector functions.

Latest News / Updates:

  • GC Biopharma continues global expansion — established plasma centers in the U.S. for IVIG and albumin manufacturing, potentially accelerating clinical development timelines.

Regulatory:

  • Domestic Korean regulatory clearances for plasma-derived products are ongoing; explicit current Phase 3 registry involvement suggests advancement in IVIG development. 

Intravenous Immunoglobulin Market Access

Hospital pharmacies currently account for the majority of IVIG product distribution. However, specialty pharmacies are projected to experience significant growth throughout the forecast period, reflecting changing healthcare delivery models and an increased focus on specialized patient management for immunoglobulin replacement therapy.

The report also evaluates reimbursement frameworks across various geographies, emphasizing the importance of proactive reimbursement strategies in supporting late-stage development and successful commercialization. A clear understanding of payer environments enables stakeholders to identify high-value indications, target markets with favorable reimbursement policies, and minimize access-related barriers.

Review the latest developments in the IVIG treatment landscape @ Intravenous Immunoglobulin Recent Developments - https://www.delveinsight.com/sample-request/intravenous-immunoglobulin-market?utm_source=apac&utm_medium=pressrelease&utm_campaign=akpr 

Conclusion

DelveInsight’s comprehensive assessment incorporates primary research and expert perspectives to validate treatment trends and market dynamics, enabling clients to better understand the overall competitive environment and areas of unmet need. The report’s competitive intelligence framework leverages analytical tools such as SWOT analysis, PESTLE analysis, and Porter’s Five Forces to provide strategic guidance for market participants.

Looking forward, the IVIG market is expected to continue evolving through enhanced disease insights, innovative therapeutic approaches, and sustained investment from key industry players. The introduction of new therapies is anticipated to reshape the competitive landscape, delivering improved options for patients with immune deficiencies while addressing persistent treatment gaps.

DelveInsight’s analysis highlights significant growth potential for more effective and accessible IVIG solutions, positioning the market for sustained expansion and therapeutic advancement over the coming decade.

Table of Contents

  1. Intravenous Immunoglobulin Market Report Introduction

  2. Executive Summary for Intravenous Immunoglobulin

  3. SWOT Analysis of Intravenous Immunoglobulin

  4. Intravenous Immunoglobulin Patient Share (%) Overview at a Glance

  5. Intravenous Immunoglobulin Market Overview at a Glance

  6. Intravenous Immunoglobulin Disease Background and Overview

  7. Intravenous Immunoglobulin Epidemiology and Patient Population

  8. Country-Specific Patient Population of Intravenous Immunoglobulin

  9. Intravenous Immunoglobulin Current Treatment and Medical Practices

  10. Intravenous Immunoglobulin Unmet Needs

  11. Intravenous Immunoglobulin Emerging Therapies

  12. Intravenous Immunoglobulin Market Outlook

  13. Country-Wise Intravenous Immunoglobulin Market Analysis (2019–2032)

  14. Intravenous Immunoglobulin Market Access and Reimbursement of Therapies

  15. Intravenous Immunoglobulin Market Drivers

  16. Intravenous Immunoglobulin Market Barriers

  17. Intravenous Immunoglobulin Appendix

  18. Intravenous Immunoglobulin Report Methodology

  19. DelveInsight Capabilities

  20. Disclaimer

  21. About DelveInsight

About DelveInsight

DelveInsight is a prominent market research and consulting organization focused on delivering disease-specific insights and therapeutic market intelligence. Its reports combine real-world evidence, clinical trial analysis, and expert interviews to provide comprehensive and actionable industry insights.